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OBJECTIVES The study was done to determine the prevalence of pulmonary emboli (PE) in asymptomatic
adult Fontan patients and to identify the risk factors associated with PE.
BACKGROUND Right atrial thrombi and systemic thromboembolic complications have been reported after the
Fontan procedure. However, the frequency of silent PE in this patient population is not
known.
METHODS All consecutive adult Fontan patients attending the adult congenital clinic over a six-month
period underwent ventilation-perfusion (VQ) scanning and blood testing for thrombophilia
tendency. If the VQ scan showed an intermediate or high probability for PE, a computerized
tomography (CT) pulmonary angiogram was performed to confirm the presence of PE.
RESULTS Thirty patients (mean age 26  7 years, 57% men) were included in this study. Five (17%)
adult Fontan patients had an intermediate or high probability for PE on VQ scan, all of which
were confirmed on CT pulmonary angiography. No patient had a thrombophilia tendency.
Pulmonary emboli were not present in any patients (30%) taking warfarin. Late age at time
of Fontan operation (19  6 years vs. 11  6 years, p  0.012) and type of Fontan anatomy
(p  0.001) were associated with increased risk of silent PE.
CONCLUSIONS Seventeen percent of adult patients with Fontan procedure have clinically silent PE. The
long-term hemodynamic implications of this with respect to Fontan attrition over time are
unknown. Large randomized prospective studies looking at anticoagulation therapy in all
Fontan patients are urgently needed. (J Am Coll Cardiol 2003;41:2252–8) © 2003 by the
American College of Cardiology Foundation
The Fontan procedure was initially described by Fontan and
Baudet in 1971 for the surgical management of tricuspid
atresia (1). The principle of the Fontan operation is the
diversion of systemic venous return directly to the pulmo-
nary arteries (PA), bypassing the pulmonic ventricle when
the latter is nonexistent, too small, or dysfunctional (2).
Numerous variations exist in the surgical approach. The
most likely types of Fontan procedure to be encountered
today are: 1) the direct right atrium (RA)–PA connection;
2) the total cavopulmonary connection (superior vena cava
to PA and inferior vena cava to PA through an intra-atrial
tunnel); and 3) the extracardiac conduit (superior vena cava
to PA and inferior vena cava to PA through an external
conduit). Thrombi and thromboembolic complications have
been reported after the Fontan operation, and modifications
of the original atriopulmonary procedure have been devel-
oped to prevent this and other longer-term complications
(3–5).
Studies have determined the point prevalence of atrial
thrombus using echocardiography (6–10). However, to date
the frequency of silent pulmonary emboli (PE) has not been
investigated. Over time some recipients of the Fontan
operation will have failure of the previously functional
Fontan circuit. The underlying causes have been attributed
to disturbed flow dynamics or ventricular dysfunction.
Occult PE could cause increasing pulmonary vascular resis-
tance and inefficiency of the Fontan circulation, but the
prevalence of silent PE in the Fontan population is un-
known. This study aimed to determine the prevalence of
silent PE in the adult Fontan population and to identify the
predisposing risk factors.
METHODS
Patient characteristics. The study included all consecutive
adult patients with a modified Fontan procedure who were
seen for routine follow-up between November 2001 and
April 2002 at the University of Toronto Congenital Cardiac
Center for Adults. Informed consent was obtained from all
participants. Patients with acute symptomatic PE were
excluded.
Patient age, gender, operative details of the Fontan
procedure, New York Heart Association functional class,
current prescription medications, oxygen saturation moni-
toring in room air (after 5 min of rest), and electrocardiog-
raphy were recorded. Complete two-dimensional transtho-
racic echocardiography (TTE) and Doppler study were
performed in all patients. The TTE was performed using a
Hewlett-Packard model 5500 with standard views. The
presence of right atrial clot was recorded. Ventricular
function was assessed qualitatively and graded 1 (normal), 2
(mild dysfunction), 3 (moderate impairment), and 4 (severe
impairment).
Blood testing. Patients were screened for hypercoagulable
abnormalities including deficiencies of protein C, protein S,
antithrombin 3, and for antiphospholipid syndrome. Pro-
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tein C and protein S levels were not included in the analysis
if the patient was taking warfarin. Packed cell volume and
albumin as a percentage of total protein were measured.
Ventilation-perfusion (VQ) scan. The VQ scan protocol
was based upon the published reports for Fontan patients
(11–15). Planar lung imaging in six projections was per-
formed for both ventilation and perfusion scans. Images
were acquired using an ADAC Forte large field-of-view
gamma camera interfaced to a PEGASYS processing sta-
tion (Phillips Medical, Malpedia, California). For the ven-
tilation images, the patient breathed through a CADEMA
aerosol unit (Tri-Bor Medical, New York, New York)
containing Tc-99m DTPA, for 3 min. Following the
ventilation images, the patient was injected with Tc-99m
macroaggregates into the right arm and any foot vein so as
to prevent false positive diagnoses due to preferential blood
flow from the superior vena cava to the right PA and
inferior vena cava to the left PA. Perfusion images were
then performed in the same projections as the ventilation
scan. The VQ scan was interpreted by an experienced
nuclear medicine physician (A.L.H.) and classified as nor-
mal, very low probability, low probability, intermediate
probability, and high probability for PE using modified
Prospective Investigation of Pulmonary Embolism Diagno-
sis criteria (16). If the VQ scan was classified as either
intermediate or high probability, the patient was requested
to undergo a computerized tomography (CT) pulmonary
angiogram to confirm the presence of PE using a PE
protocol.
Computerized tomography. A CT pulmonary angiogram
was performed on a multidetector spiral scanner (Light-
speed, General Electric, Milwaukee, Wisconsin). The pa-
tient was placed supine with the arms extended behind the
head. Bilateral 18-g cannulas were inserted into antecubital
veins and connected to a power injector (Medrad, Pitts-
burgh, Pennsylvania). Frontal and lateral scout views (120
kV, 10 mA) were used to plan the limits of the CT
pulmonary angiogram from the dome of the diaphragm to
the sternoclavicular joints.
A timing bolus was performed during free breathing
using 15 cc of iohexol 65% (Omnipaque 300 mg/ml,
Nycomed, Oslo, Norway) injected at 5 cc/l in order to
determine the contrast peak in the area of interest. In a
patient with normal cardiac anatomy, peak contrast would
be at the level of the PA bifurcation. Because of the altered
cardiac anatomy in the Fontan patients, this timing bolus
was performed in the left atrium at the insertion of the
inferior pulmonary veins. The time delay between the
injection of contrast agent and image acquisition was then
determined and the patient given instructions to perform a
breath hold in inspiration during image acquisition. The
patient was then injected with 60 to 80 cc of iohexol 65% at
5 cc/s, and image acquisition was commenced in a caudal-
cranial direction.
The acquisition parameters were a 512  512 matrix, 2.5
 1.5 mm slice width, a table speed of 7.5 to 15 mm/s in
HS mode, 120 kV and 300 to 420 mA. The volume of
injected contrast agent, table speed, and exposure factors
varied with the patient body habitus. Soft-copy images were
interrogated using scroll mode on a stand-alone PACS
workstation by an experienced chest radiologist (N.S.P.).
The diagnosis of acute or chronic thromboembolic disease
was made in accordance with published criteria (17–19).
Statistical analysis. The primary end point was presence or
absence of PE. Comparison between those with PE and
without PE was made with independent t test (equal
variances not assumed) for continuous variables and the
Fisher exact test for categorical variables. Comparison
between multiple groups was performed with a Kruskal-
Wallis test. Values are expressed as mean  1 SD. Logistic
regression was performed to test whether variables were
associated with the presence of a PE. A p value  0.05 was
considered statistically significant (two-sided).
RESULTS
Patient characteristics. A total of 44 adult patients with
modified Fontan procedure were seen in our adult congen-
ital clinic during this period. Three patients had a diagnosis
of symptomatic PE during this study period, and they were
excluded from the study (two patients were known for atrial
flutter on Coumadin and presented with acute shorteness of
breath, and one patient not anticoagulated presented with
hemoptysis and desaturation). Of the remaining 41 patients
requested to participate in this study, 31 consented and 10
declined. One of the VQ studies for a patient was incom-
plete and was excluded from the analysis. Therefore, 30
patients in total were studied.
The mean baseline characteristics are described in Table
1. The mean age of the study group was 26 7 years (range
18 to 45 years). The mean age at the time of the last Fontan
operation was 12  7 years. All patients were in either New
York Heart Association functional class 1 (23 patients) or
class 2 (7 patients). Ventricular function was graded as 1 or
2 in 24 (80%) patients on TTE.
Individual anatomy, surgery, and anticoagulation indica-
tions are shown in Table 2. Atrial flutter or fibrillation,
either chronic or paroxsymal, was present in nine patients
(30%). Three patients had a past history of right atrial clot,
and one other patient had residual thrombus detectable in
the right atrium on TTE. In total, nine subjects were taking
warfarin and two were on aspirin.
Abbreviations and Acronyms
CT  computerized tomography
PA  pulmonary artery
PE  pulmonary embolus/emboli
RA  right atrium
RV  right ventricle
TTE  transthoracic echocardiography
VQ  ventilation perfusion
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Hematologic values. Mean packed cell volume was 44 
5% (normal range 40% to 54%). The mean albumin as a
percentage of total protein was 59  4% (normal 50% to
70%). In those patients not on warfarin (n 21), no patient
was found to have deficiency of protein C or protein S. No
patient had abnormal antithrombin levels. No patient was
positive for antiphospholipid antibodies or anticardiolipin
antibodies.
The VQ scan. The VQ scan was normal in 18 patients,
low probability in 7 patients, intermediate probability in 3
patients, and high probability in 2 patients. In all five
patients (17%) with an intermediate or high probability
study, CT pulmonary angiogram was undertaken, and PE
was confirmed in all these patients. Distribution of the PE
and the patient characteristics for those with PE are shown
in Table 3. Figure 1 depicts an example of a VQ scan and
CT pulmonary angiogram from one of the patients.
Univariate analysis. Older age at the time of the Fontan
operation was associated with the presence of PE (age 19 
6 vs. 11  6 years, p  0.012) as well as the type of Fontan
correction (atriopulmonary 0/18, RA–RV 2/6, and lateral
tunnel 3/4, p  0.001). No patient on warfarin had a PE.
Not associated with PE were atrial arrhythmias, right atrial
thrombus, or previous systemic thrombotic events.
DISCUSSION
Prevalence of PE. The prevalence of silent PE in adult
patients with the Fontan operation was unknown until now.
The findings of this study reveal a one in six chance of a
silent PE being present in asymptomatic adult Fontan
patients. It is of interest to note that no patients on
coumadin (n  9) were diagnosed with an asymptomatic
PE, raising the prevalence of silent PE in nonanticoagulated
Fontan patients to 24% (5/21). The lifetime prevalence of
asymptomatic PE in these patients may well be even greater
as this study only looked at the prevalence at one point in
time (20). Furthermore, each CT pulmonary angiogram
performed confirmed the VQ scan result, implying the study
threshold for CT scanning may have been too high, and
changing this to include those with a lower probability for
PE on VQ scan, which might have yielded more patients
with asymptomatic PE. Finally, the total occurrence of
PE—both symptomatic and asymptomatic—is actually still
higher than one in six in the Fontan population, as this
study excluded those with symptomatic PE.
The technique to determine the presence of PE is of great
consequence. Ventilation perfusion scanning was chosen as
the screening test in our study because of its availability,
simplicity, safety, and comfort for the patient, and for its
relatively good sensitivity and specificity as a screening test
in non-Fontan patients. The imaging methodology was
designed to prevent false positive diagnoses. Misinforma-
tion regarding pulmonary flow patterns can occur because of
preferential blood flow from the superior vena cava to the
right PA and from the inferior vena cava to the left PA. In
our center, Fontan patients have been referred with a
diagnosis of acute PE on imaging, which has subsequently
been proven to be an artefact due to isotope injection from
the arm only. This problem may be resolved by injection of
macroaggregates for perfusion scanning into the arm and
any foot vein. The timing of image acquisition with contrast
during CT pulmonary angiography is also critical to prevent
false positive diagnoses.
Previous studies of thrombus in the Fontan population.
Thrombosis is a major cause of morbidity and mortality
after Fontan procedures. Prior cross-sectional studies look-
ing at the prevalence of thrombus within the right atrium
after Fontan procedures have reported a prevalence of
thrombi varying anywhere between 9% and 33% (7–10).
The highest prevalence of thrombi in the right atrium was
observed when transesophageal echocardiography was used
to detect thrombus (9), and the lower prevalence occurred
using TTE (10).
Studies of venous thromboembolic events as a primary
outcome in Fontan patients have quoted incidences ranging
from 5% to 16% (21–25). The higher incidences are in more
recent studies, reflecting a longer duration of follow-up,
and/or increased awareness of the potential for thrombosis
with improved diagnostic testing. Presentation may be
embolus to the lung, obstruction to flow in the right atrium,
or peripheral venous thrombosis. The finding from this
study of a 17% prevalence of silent PE would be consistent
with the previously published data.
Risk factors for PE occurrence. Following the Fontan
operation there may be a low flow state, stasis in venous
pathways, right to left shunts, blind cul de sacs, prosthetic
materials, and/or atrial arrhythmia as risk factors for throm-
bophilia (26). In addition, some studies have demonstrated
a prothrombotic tendency in Fontan patients (27–30). We
Table 1. Baseline Characteristics of Patients
Total cohort (n)
Mean age (yrs) 26  7
Male gender 17 (57%)
Mean age at Fontan operation (yrs) 12  7
Fontan anatomy
Atriopulmonary connection 18 (60%)
RA–RV conduit 6 (20%)
Lateral tunnel 4 (13%)
Other 2 (7%)
NYHA functional class
1 23 (77%)
2 7 (23%)
Mean oxygen saturation on room air 94  4%
History of arrhythmia
Atrial flutter 7 (23%)
Atrial fibrillation 2 (7%)
Ventricular function (grade)
1 or 2 24 (80%
3 or 4 6 (20%)
Medication (at time of VQ scan)
Warfarin 9 (30%)
Aspirin 2 (7%)
NYHA  New York Heart Association; RA–RV  right atrium–right ventricle;
VQ  ventilation perfusion.
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Table 2. Summary of the Individual Patient Characteristics
Patient
No. Original Anatomy Age Gender Fontan Anatomy
Age at
Operation
Years Since
Fontan
Procedure Warfarin or Aspirin
Anticoagulation
Indication
1 Congenitally corrected TGA 22 M AP 9 13
2 TGA/VSD 19 M AP 8 11
3 Tricuspid atresia 45 M RA–RV (nonvalved) 27 18
4 Congenitally corrected TGA/VSD/
double outlet RV/pulmonary
stenosis
21 M AP 6 15
5 Hypoplastic RV 30 M AP 16 14
6 Congenitally corrected
TGA/pulmonary stenosis
28 F Complex 14 14 W Conduit thrombus
7 Univentricular heart 19 F AP 6 13
8 Tricuspid atresia 23 F AP 9 14 W CAF/RA thrombus
9 Univentricular
heart/TGA/pulmonary stenosis
22 M AP 8 14
10 Pulmonary atresia 19 F AP 5 14 W CAFL
11 Hypoplastic RV/TGA 31 M AP 15 16
12 Tricuspid atresia 42 F RA–RV 32 10
13 Univentricular heart 22 F LT (extracardiac) 21 1 A PAFL
14 Tricuspid atresia 18 F AP 6 12
15 Double inlet LV/VSD 22 F AP 8 14 PAFL
16 Tricuspid atresia/TGA 19 M AP 6 13
17 Tricuspid atresia 28 M AP 14 14 W CAFL
18 Tricuspid atresia 34 M AP 17 17 W PAFL
19 Tricuspid atresia 38 M RA–RV 17 21 W PAFL
20 AVSD/pulmonary atresia 23 F LT 9 14
21 Tricuspid atresia 33 F RA–RV (nonvalved) 15 18 W CAF/RA thrombus
22 Univentricular heart/TGA 23 F AP 8 15 A RA thrombus
23 Double inlet LV 21 M LT (extracardiac) 7 14
24 Tricuspid atresia/TGA 25 M Complex 7 18 W PAFL
25 Hypoplastic RV 22 M LT 19 3
26 Tricuspid atresia 22 M AP 8 14
27 Tricuspid atresia/TGA 24 M AP 9 15
28 Tricuspid atresia 24 F RA–RV 8 16 W Nil
29 Double inlet LV 23 M RA–RV (nonvalved) 18 5
30 Mitral atresia, hypoplastic LV 18 F AP 5 13
A  aspirin; AP  atriopulmonary; AVSD  atrioventricular septal defect; CAF  chronic atrial fibrillation; CAFL  chronic atrial flutter; LT  lateral tunnel; LV  left ventricle; PAF  paroxsymal atrial fibrillation; PAFL 
paroxysmal atrial flutter; RA  right atrium; RV  right ventricle; TGA  transposition of the great arteries; VSD  ventricular septal defect; W  warfarin.
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were surprised to find that a prothrombotic tendency was
not observed in our adult patient population, either in those
with or without PE, although those on warfarin did not
have a complete screen. In some of the studies showing a
prothrombotic tendency in a pediatric Fontan population, a
normal adult range was used as a reference instead of normal
pediatric values, and it has been stated that no accurate data
implicate abnormalities of the coagulation system in throm-
boembolism after Fontan procedures (6). In one study (29),
the extent of prothrombotic tendency was observed to be
less in patients with longer follow-up, which may support
our thrombophilia data. The lack of a prothrombotic
tendency within our population implies that chronic PE
formation may be a flow-related phenomena as opposed to
an abnormal hematological tendency. Further in vitro and in
vivo studies of flow hemodynamics in Fontan models and
patients are needed to clarify the contribution of the
so-called low flow state physiology to the prothrombotic
tendency seen in these patients.
Our findings of the association of PE with an older age at
the time of Fontan operation and lateral tunnel surgery need
further confirmatory studies. Other studies with a high
incidence of atrial thrombus did not identify predictors of
thrombus formation (8–10). Higher left ventricular, end-
diastolic pressure from prolonged volume overload condi-
tion or chronic cyanosis in patients operated on at a later age
Table 3. Characteristics of Those Patients With Pulmonary Emboli
Patient
No.
Age of
Patient (yrs)
Age at
Surgery (yrs)
Type of
Surgery
NYHA
Functional
Class
Location of
PE (Lobe)
3 45 27 RA–RV 2 left lower
13 22 21 LT 1 right upper
20 23 9 LT 1 left upper
25 22 19 LT 1 right upper
29 23 18 RA–RV 1 right lower
LT  lateral tunnel; NYHA  New York Heart Association; PE  pulmonary embolus; RA  right atrium; RV  right
ventricle.
Figure 1. Left anterior oblique projections of the ventilation (A) and perfusion (B) images illustrate a perfusion defect in the left upper lobe (thin arrow,
B), in Patient 20. This is indicative of a high probability for pulmonary embolus. Coronal (C) and sagittal oblique (D) maximum intensity projections from
the computerized tomography pulmonary angiogram are shown. In the coronal projection (C), gradation of vessel contrast from the lower lobe to the upper
lobe vessels is seen, and relative paucity of contrast within the upper lobe pulmonary arteries on the left compared to the right is shown near the asterisk.
Endoluminal filling defect, in keeping with thrombus, is shown within a segmental upper lobe pulmonary artery (dashed arrow, C and D). Incidental
nonocclusive thrombus is also seen in this patient in a lower lobe pulmonary artery (thick arrow, C).
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might predispose these patients to higher pulmonary vas-
cular resistance and greater right atrial stasis. Likewise, the
use of Dacron material in the lateral tunnel may act as a
nidus for clot formation. Modifications to the original
atriopulmonary Fontan procedure (lateral tunnel and exter-
nal conduit) have been developed to prevent in part the
prothrombotic complications of the RA to PA Fontan
connection. It is of interest to note that none of our patients
with an RA to PA connection were found to have an
asymptomatic PE.
Anticoagulation and the Fontan patient. Despite our
results and previous reports on the incidence of thrombi in
this patient population, the role of long-term prophylactic
anticoagulation in the Fontan patients remains controver-
sial. The evidence to prescribe warfarin to all patients with
the Fontan operation will continue to be poor without
proper randomized controlled studies (6). Results of cohort
studies on the effect of aspirin and/or warfarin treatment are
contradictory. In a study of 72 postoperative Fontan pa-
tients, with a median age of 25 months and treated with
aspirin only, no thrombi were detected with TTE at a mean
follow-up of 40 months (31). Conversely, the follow-up
study from Coon et al. (10) in 552 patients using TTE
showed that almost 9% of patients could develop atrial
thrombus while on aspirin or warfarin at a median follow-up
of 22 months. In our study, silent PE were diagnosed in one
patient while taking aspirin but none while taking
Coumadin.
The morbidity related to the risk of bleeding with
warfarin in this young adult population is not inconsequen-
tial, with serious bleeding in at least 0.5% per patient year
(32). The optimal international normalized ratio one should
aim for in the Fontan population is unknown. Fontan
patients required 25% lower dosage as compared with other
congenital heart disease patients in an analysis of warfarin
therapy in pediatric patients (32). Compliance with regular
medication in a young population may be inconsistent (5),
and this was reflected in the baseline data presented, in
which some patients with previous thrombi detected still
declined to take warfarin. In our study over 50% of the
cohort had at least one conventional indication (atrial
arrhythmia, right atrial clot or PE) for warfarin. Large
prospective studies comparing alternative strategies of war-
farin, aspirin, and no therapy to prevent thrombi and PE in
this patient population are urgently needed to determine
whether all Fontan patients should be anticoagulated or
whether a strategy of targeting selected patients should be
followed.
Potential implication of silent PE. The asymptomatic PE
may carry significant clinical consequences. The hemody-
namic consequence of silent emboli to the lungs is presently
unknown in this patient group. It was recently demon-
strated that pulmonary resistance rather than geometry
decides flow distribution in the modified Fontan circulation
(33). Computer simulations of the circulation in patients
with cavopulmonary connection show a marked interrela-
tion of cardiac and vascular pressure, flow, resistance, and
capacitance (34). It is suggested that higher shear stress
(from PE, for example) on the wall of the pulmonary
vasculature may alter endothelial function (that is, increase
vasoconstriction) and affect the longevity of the functional
Fontan (35). If silent PE indeed increases pulmonary
vascular resistance in these patients, any strategy to prevent
PE formation could potentially improve long-term function
of the Fontan circuit and improve survival of these patients.
Further studies into the hemodynamic consequences of PE
on the Fontan attrition rate are needed.
Study limitations. In quantifying a prevalence, bias can
occur because of selection into or out of this population.
Numbers in this study are small and conclusions regarding
predisposing factors to PE formation should be viewed with
caution because of a potential type 2 statistical error.
Additionally, we did not perform a transesophageal echo-
cardiogram concurrently to determine thrombus within the
Fontan circuit at the time of VQ scan or CT in our patients.
Although more information regarding concomitant right
atrial thrombus would have been interesting, the discomfort
engendered by transesophageal echocardiography would
have been substantial without changing the result of our
primary end point. Lastly, the relatively high incidence of
pulmonary segmental flow disturbances in these patients
from intrinsic PA stenosis or surgically created PA distor-
tion ought to make us cautious in interpreting the results of
the VQ scan, although a congenitally underdeveloped PA or
branch would most likely be associated with a proportional
decrease in ventilation and not give rise to a mismatch
defect.
Conclusions. Seventeen percent of adult patients with the
Fontan procedure have clinically silent PE. The hemody-
namic long-term implications of this with respect to Fontan
attrition over time are unknown. Large randomized pro-
spective studies looking at anticoagulation therapy in all
Fontan patients are urgently needed.
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